Compare Rocket Lab USA Inc (RKLB) vs 10X Genomics Inc (TXG) Price & Performance

Rocket Lab (RKLB) trades at $65.87, down 56% from its 52-week high, with a bearish technical signal but strong analyst support. Q2 2026 revenue grew 62% year-over-year to $234 million, yet the company posted a net loss margin of -21.51%. Recent news highlights Neutron rocket delays to 2027 and a CFO stock sale, while Cathie Wood's ARK Invest added $45 million in shares (GuruFocus, September 7, 2026).

Outlook hinges on Neutron's successful deployment and profitability by 2028, offering high growth potential but facing execution risks and cash burn. Analysts see 78% upside to a $117.44 consensus target, though technical weakness and competitive pressures warrant caution for investors seeking space exposure.

TXG trades at $65.60, up 4.71% today, with a bullish technical signal and recent earnings beats. The stock shows improving fundamentals, with 2025 revenue at $642.82M and net loss narrowing to -$43.54M. Positive sentiment is driven by patent wins, Atera platform demand, and institutional interest, though valuation metrics like P/S of 13.58 and EV/EBITDA of 142.2 remain elevated.

Outlook is cautiously optimistic with upside potential from Atera execution, but risks include high valuation, persistent losses, and competitive pressures. Analyst consensus is mixed with a $50.56 price target below current levels, indicating near-term caution despite long-term growth prospects in genomics.